Do you recommend any alternative schedule for cabozantinib to make treatment compliance easier for patients with metastatic renal cell carcinoma?

There are several considerations to remember when dosing TKIs. The first is that TKIs are not curative in mRCC, so the goal should be to give the patient the lowest possible dose that will control disease while preserving QOL. Also, patient exposure (drug levels) is extremely variable from patient t...